Gilead wins US ruling in hepatitis C patent dispute with Idenix
This article was originally published in Scrip
Executive Summary
US patent officials ruled in favor of Gilead Sciences in a long-running dispute with Idenix Pharmaceuticals over the intellectual property rights related to hepatitis C drug development.